Clevidipine

Modify Date: 2025-08-25 22:22:12

Clevidipine Structure
Clevidipine structure
 Common Name Clevidipine
CAS Number 167221-71-8 Molecular Weight 456.316
Density 1.3±0.1 g/cm3 Boiling Point 539.7±50.0 °C at 760 mmHg
Molecular Formula C21H23Cl2NO6 Melting Point 128-130°C
MSDS N/A Flash Point 280.2±30.1 °C

 Use of Clevidipine


Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.IC50 Value: 7.1 nM at V(H) = -40 mV [1]Target: calcium channelin vitro: Both clevidipine and nitroglycerin completely reversed U46619-induced contraction (clevidipine (50% effective concentration [EC50] = 3.88 +/- 0.84 x 10(-6) mol/L, nitroglycerin EC50 = 4.84 +/- 2.76 x 10(-8) mol/L) [2]. A decrease in temperature increased the half-life of clevidipine in blood, whereas dilution of the blood did not affect the in vitro half-life of clevidipine. The albumin concentration affected the hydrolysis rate of clevidipine in RBC suspended with saline [3].in vivo: Clevidipine is a high-clearance drug with a relatively small volume of distribution, resulting in an extremely short half-life in all species studied. The median initial half-life of the individual value (Bayesian estimates) is 12, 20, and 22 s in the rabbit, rat, and dog, respectively [4]. The extremely high clearance value and the small volume of distribution resulted in short half-lives of clevidipine, 2.2 and 16.8 min, respectively. The blood concentration and dose rate producing half the maximal effect (i.e. EC50 and ED50) were approximately 25 nM and 1.5 microg/kg/min, respectively [5].Clinical trial: CARVE: Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed. Phase 4

 Names

Name 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Synonym More Synonyms

 Clevidipine Biological Activity

Description Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension.IC50 Value: 7.1 nM at V(H) = -40 mV [1]Target: calcium channelin vitro: Both clevidipine and nitroglycerin completely reversed U46619-induced contraction (clevidipine (50% effective concentration [EC50] = 3.88 +/- 0.84 x 10(-6) mol/L, nitroglycerin EC50 = 4.84 +/- 2.76 x 10(-8) mol/L) [2]. A decrease in temperature increased the half-life of clevidipine in blood, whereas dilution of the blood did not affect the in vitro half-life of clevidipine. The albumin concentration affected the hydrolysis rate of clevidipine in RBC suspended with saline [3].in vivo: Clevidipine is a high-clearance drug with a relatively small volume of distribution, resulting in an extremely short half-life in all species studied. The median initial half-life of the individual value (Bayesian estimates) is 12, 20, and 22 s in the rabbit, rat, and dog, respectively [4]. The extremely high clearance value and the small volume of distribution resulted in short half-lives of clevidipine, 2.2 and 16.8 min, respectively. The blood concentration and dose rate producing half the maximal effect (i.e. EC50 and ED50) were approximately 25 nM and 1.5 microg/kg/min, respectively [5].Clinical trial: CARVE: Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed. Phase 4
Related Catalog
References

[1]. Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.

[2]. Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.

[3]. Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.

[4]. Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64.

[5]. Schwieler JH, et al. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J Cardiovasc Pharmacol. 1999 Aug;34(2):268-74.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 539.7±50.0 °C at 760 mmHg
Melting Point 128-130°C
Molecular Formula C21H23Cl2NO6
Molecular Weight 456.316
Flash Point 280.2±30.1 °C
Exact Mass 455.090240
PSA 90.93000
LogP 5.46
Vapour Pressure 0.0±1.4 mmHg at 25°C
Index of Refraction 1.543
InChIKey KPBZROQVTHLCDU-UHFFFAOYSA-N
SMILES CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
Storage condition Refrigerator

 Safety Information

Hazard Codes Xi
Safety Phrases 24/25

 Synonyms

(butanoyloxy)methyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Cleviprex
clevidipine
(±)-Hydroxymethyl Methyl 4-(2,3-Dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate Butyrate (Ester)
Methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
Clevidipine butyrate
Clevidipine,Cleviprex
H 324/38
(Butyryloxy)methyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
Clevelox
3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester
rac-Clevidipine
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Clevidipine suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Clevidipine price

Related Compounds: More...
Clevidipine
166432-28-6
3-(1-ethyl-1H-pyrazol-4-yl)pentanedioic acid
2228188-40-5
2,2,2-trifluoro-1-(1H-indazol-3-yl)ethan-1-amine
2228712-84-1
2-(4-Fluoropyridin-2-yl)ethanimidamide
2229552-81-0
Methyl 2-amino-2-(4-bromo-3-methoxyphenyl)acetate
2111982-21-7
tert-butyl N-[2-(aminomethyl)-3,4,4,4-tetrafluorobutyl]carbamate
2229481-93-8
5-(2,5-Dioxooxolan-3-yl)thiophene-3-carbonitrile
2229022-33-5
3-[(2-methyl-2H-indazol-3-yl)methyl]azetidin-3-ol
2229232-52-2
4-[4-(Dimethylamino)-3-fluorophenyl]-1,3-oxazolidin-2-one
2229481-99-4
2-[1-(4-Bromo-2-methylphenyl)cyclobutyl]ethan-1-amine
2228529-25-5
(3S)-3-(5-chloro-2-ethoxyphenyl)-3-hydroxypropanoic acid
2227910-86-1
Chemsrc provides Clevidipine(CAS#:167221-71-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Clevidipine are included as well.>> amp version: Clevidipine

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved